摘要
利福平(简称 Rifan)分别与过氧化苯甲酰(BPO)和过氧化月桂酰(LPO)组成的氧化还原引发体系,能在较温和的条件下引发烯类单体聚合,形成控释给药药膜,从而避免了在剧烈条件下聚合成型可能导致药物结构受破坏,又可避免一般含小分子胺的氧化还原引发体系的引入.实验证明:BPO—Rifam、LPO—Rifam 体系的活化能分别为45.9 kJ/mol 和48.2 kJ/mol(40～60℃),低于纯(?)体系的活化能;且 BPO—Rifam 体系能在40℃温度下引发烯类单体聚合,形成控释药膜,该药膜体内相容性良好.
A new type of redox initiator—drug/peroxide initiator was described,which can be applied in controlled drug delivery system.This system,was very good for developing peroxide-heterocyclie tertiary amine redox system.Kinetics of pelymerization of MMA initiated by BPO-Rifampin(Rifam) and LPO-Rifam was investigated.We Used BPO-Rifam to initiate comonomers HEMA-MMA and obtained a drug-membrane.Polymerization was carried out at 40℃.Some in vitro test on drug releases were carried out.We also studied the in vivo drug release and.biocompatibility of the drug membrane toward tissue.Mistological examinations were made on surrounding tissues.
出处
《暨南大学学报（自然科学与医学版）》
CAS
CSCD
1992年第3期54-61,共8页
Journal of Jinan University(Natural Science & Medicine Edition)
关键词
利福平
氧化还原
有机过氧化物
rifampin
redox initiate system
teterocyclio tertiary amine
